23 completed, 11 unknown, 5 terminated, 2 withdrawn. 12 Phase 2, 10 Phase 3, 4 Phase 4, 2 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 8, Terminated 3, Unknown 1 |
| Phase 3 | 10 | Completed 5, Terminated 2, Withdrawn 2, Unknown 1 |
| Phase 4 | 4 | Completed 4 |
| Not applicable | 2 | Unknown 2 |
| Phase 1 | 1 | Completed 1 |
Follow Bullous Pemphigoid: new trials by email Literature Review of Bullous Pemphigoid trials Research Report on Bullous Pemphigoid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Retrospective Study of the Effects of Sub-pathologic Phenotypes of BP on Clinical Management and Prognosis This is a retrospective analysis of health data from inpatient record, no intervention was designed - Bullous Pemphigoid | Unknown | Xijing Hospital | 318 | 2024-01-11 | 2024-01-19 | |
| Efficacy and Safety of add-on Dapsone Versus add-on Methotrexate in Patients With Bullous Pemphigoid Prednisolone, Dapsone, Methotrexate - Bullous Pemphigoid | Phase 4 | Completed | All India Institute of Medical Sciences, Bhubaneswar | 62 | 2023-08-01 | 2025-08-14 |
| A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid efgartigimod PH20 SC, Prednisone - Bullous Pemphigoid | Phase 3 | Terminated | argenx | 64 | 2023-03-22 | 2026-02-25 |
| Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid Ozonated olive oil, Topical garamycin cream - Pemphigus Vulgaris, Bullous Pemphigoid | Phase 3 | Unknown | Cairo University | 30 | 2022-11-01 | 2022-11-08 |
| Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid Dupilumab - Bullous Pemphigoid | Completed | Peking University First Hospital | 146 | 2022-09-01 | 2023-12-04 | |
| Validation of a Simplified Severity Score (Investigator Global Assessment: IGA) in Bullous Pemphigoid IGA score, BULLOUS PEMPHIGOID DISEASE AREA INDEX (BPDAI) - Bullous Pemphigoid | Unknown | University Hospital, Rouen | 150 | 2022-07-01 | 2022-05-09 | |
| A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid efgartigimod PH20 SC, placebo, Prednisone - Bullous Pemphigoid | Phase 2 / Phase 3 | Completed | argenx | 98 | 2022-06-09 | 2025-10-23 |
| Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP) nomacopan (rVA576), Placebo - Bullous Pemphigoid | Phase 3 | Withdrawn | AKARI Therapeutics | 2022-05-06 | 2025-04-09 | |
| Deciphering IL-17-dependant Inflammatory Response in Bullous Pemphigoid Blood sampling, Liquid bubble sampling, Cutaneous biopsy - Bullous Pemphigoid | Not applicable | Unknown | CHU de Reims | 140 | 2022-02-10 | 2024-06-27 |
| JAK Inhibitors' Efficacy in Bullous Pemphigoid Janus Kinase Inhibitor - Bullous Pemphigoid, Janus Kinase Inhibitor | Completed | Chao Ji | 120 | 2022-01-01 | 2024-09-05 | |
| A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid. Benralizumab, Placebo - Bullous Pemphigoid | Phase 3 | Terminated | AstraZeneca | 67 | 2021-03-31 | 2024-11-29 |
| Telederm and Bullous Pemphigoid Bullous Pemphigoid | Completed | Emory University | 21 | 2021-03-15 | 2023-10-13 | |
| Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid bone densitometry, blood test, radiographs of the thoracic and lumbar spine - Osteoporosis, Bullous Pemphigoid | Phase 4 | Completed | Centre Hospitalier Universitaire, Amiens | 50 | 2020-12-11 | 2026-09-08 |
| A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid dupilumab, Matching Placebo, Oral corticosteroids (OCS) - Bullous Pemphigoid | Phase 2 / Phase 3 | Completed | Regeneron Pharmaceuticals | 106 | 2020-10-28 | 2026-06-18 |
| Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody Avdoralimab (IPH5401), Control - Bullous Pemphigoid | Phase 2 | Completed | Centre Hospitalier Universitaire de Nice | 15 | 2020-10-10 | 2026-03-24 |
| Bullous Pemphigoid Induced by antiPD-1/PDL-1 Therapy Not concerned - Bullous Pemphigoid, Immunotherapy | Unknown | Nantes University Hospital | 85 | 2020-04-01 | 2020-11-24 | |
| Efficacy and Safety of Ustekinumab in Bullous Pemphigoid Ustekinumab - Bullous Pemphigoid | Phase 2 | Completed | CHU de Reims | 18 | 2020-03-11 | 2023-08-08 |
| Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid? data report - Bullous Pemphigoid | Unknown | Assistance Publique Hopitaux De Marseille | 183 | 2018-09-01 | 2018-08-17 | |
| Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid Bullous Pemphigoid | Completed | University Hospital, Brest | 63 | 2017-11-07 | 2019-01-07 | |
| A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid AC-203 1% Topical Ointment, Clobetasol 0.05% Topical Ointment - Bullous Pemphigoid | Phase 2 | Terminated | TWi Biotechnology, Inc. | 10 | 2017-09-05 | 2019-09-19 |
Showing 20 of 43. Sign in to see all of them.
Pemphigoid, Bullous (43) · Pemphigus (3) · Pruritus (3) · Autoimmune Diseases (2) · Blister (2) · Skin Diseases (2) · Eosinophilia (1) · Immune System Diseases (1) · Nervous System Diseases (1) · Osteoporosis (1) · Rare Diseases (1) · Stevens-Johnson Syndrome (1) · Urticaria (1)
Skin Diseases, Vesiculobullous (43) · Skin and Connective Tissue Diseases (43) · Immune System Diseases (42) · Autoimmune Diseases (41) · Skin Diseases (41) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (3) · Skin Manifestations (3) · Hypersensitivity (2) · Pathological Conditions, Anatomical (2) · Bone Diseases (1) · Bone Diseases, Metabolic (1) · Chemically-Induced Disorders (1) · Dermatitis (1) · Disease Attributes (1)
Prednisone (4) · Blood Specimen Collection (3) · Clobetasol (3) · Methotrexate (3) · dupilumab (3) · Omalizumab (2) · Rituximab (2) · 2'-((4'-trifluoromethanesulfonyloxy)phenyl)-N-methanesulfonylpropionamide (1) · Adrenal Cortex Hormones (1) · Azathioprine (1) · Dapsone (1) · Dipeptidyl-Peptidase IV Inhibitors (1) · Doxycycline (1) · Electronic Health Records (1) · Hematologic Tests (1)
CHU de Reims (6) · University Hospital, Rouen (4) · Nihon Pharmaceutical Co., Ltd (2) · Regeneron Pharmaceuticals (2) · argenx (2) · AKARI Therapeutics (1) · All India Institute of Medical Sciences, Bhubaneswar (1) · Assistance Publique Hopitaux De Marseille (1) · AstraZeneca (1) · Cairo University (1) · Centre Hospitalier Universitaire de Nice (1) · Centre Hospitalier Universitaire, Amiens (1) · Chao Ji (1) · Dompé Farmaceutici S.p.A (1) · Duke University (1)
France (21) · United States (12) · Germany (8) · Japan (7) · China (6) · Australia (4) · Greece (4) · Israel (4) · Italy (4) · Spain (4) · Taiwan (4) · Bulgaria (3) · Netherlands (3) · Poland (3) · Croatia (2)
Aaron Mangold, MD (1) · Aikaterini Kountouri, MD (1) · Andrea Kneisel, MD (1) · Benjamin Batteux, MD (1) · Biagio Didona, MD (1) · Catherine Lok, Pr (1) · Chao Ji, PhD (1) · Detlef Zillikens, MD (1) · Emanual Maverakis, MD (1) · Emmanouil Korakas, MD (1) · Evangelia Papadavid, MD,PhD (1) · Gang Wang, Phd (1)
PMID 18087004, PMID 30837635, PMID 38443648, PMID 38508975, PMID 39310808, PMID 41807108
2014 (1), 2019 (1), 2023 (1), R01AR076089 (1)